Drug IP Owner Says Boehringer's Overcharge Claim Is Capped

Law360, London (September 10, 2020, 5:00 PM BST) -- Licensing company Royalty Pharma has admitted that it overcharged Boehringer Ingelheim patent royalties for sales of its diabetes treatment, but argued in its lawsuit over unpaid money that anything it owed the German drugmaker was limited by the three-year deadline for filing a claim.

The patent licensing company admitted in a filing at the High Court hitting back at Boehringer's counterclaims that it should not have charged royalties based on the drug company's global sales. But it argued that anything that Boehringer can claim back is subject to a three-year statute of limitations.

The dispute is rooted in a 2005 licensing deal between...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!